Related references
Note: Only part of the references are listed.AXL/MERTK inhibitor ONO-7475 potently synergizes with venetoclax and overcomes venetoclax resistance to kill FLT3- ITD acute myeloid leukemia
Sean M. Post et al.
HAEMATOLOGICA (2022)
Soluble AXL is a novel blood marker for early detection of pancreatic ductal adenocarcinoma and differential diagnosis from chronic pancreatitis
Neus Martinez-Bosch et al.
EBIOMEDICINE (2022)
AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis
Marie-Anne Goyette et al.
CANCERS (2022)
Repurposing existing therapeutics, its importance in oncology drug development: Kinases as a potential target
Saiful Islam et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2022)
Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition
Agnete S. T. Engelsen et al.
FRONTIERS IN IMMUNOLOGY (2022)
Design and Synthesis of 5-Aryl-substituted Phenylpyrimidine-2,4-diamine Derivatives as Novel Mer and Tyro3 Kinase Inhibitors
Yeonji Kim et al.
BULLETIN OF THE KOREAN CHEMICAL SOCIETY (2021)
AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew
Almira Auyez et al.
CANCERS (2021)
Targeting MERTK and AXL in EGFR Mutant Non-Small Cell Lung Cancer
Dan Yan et al.
CANCERS (2021)
Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor
Hefeng Zhang et al.
JOURNAL OF MEDICINAL CHEMISTRY (2021)
Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine derivatives as novel selective Axl inhibitors
Satoshi Inoue et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2021)
Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation
Dandan Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2021)
Development of the phenylpyrazolo[3,4-d]pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor
Ho Jin Lee et al.
THERANOSTICS (2021)
Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker
Congjun Xu et al.
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY (2020)
ONO-7475, a Novel AXL Inhibitor, Suppresses the Adaptive Resistance to Initial EGFR-TKI Treatment in EGFR-Mutated Non-Small Cell Lung Cancer
Naoko Okura et al.
CLINICAL CANCER RESEARCH (2020)
Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment
Mai Tanaka et al.
CANCERS (2020)
AXL Receptor in Breast Cancer: Molecular Involvement and Therapeutic Limitations
Italia Falcone et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2020)
Targeting Tyro3, Axl and MerTK (TAM receptors): implications for macrophages in the tumor microenvironment
Kayla V. Myers et al.
MOLECULAR CANCER (2019)
Axl signaling is an important mediator of tumor angiogenesis
Mai Tanaka et al.
Oncotarget (2019)
The stromal microenvironment provides an escape route from FLT3 inhibitors through the GAS6-AXL-STAT5 axis
Anna Orlova et al.
HAEMATOLOGICA (2019)
AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications
Chenjing Zhu et al.
MOLECULAR CANCER (2019)
Cancer statistics, 2019
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2019)
Stromal Gas6 promotes the progression of premalignant mammary cells
Angelica M. Gomes et al.
ONCOGENE (2019)
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer
Louise A. Koopman et al.
JCI INSIGHT (2019)
Targeting AXL kinase with TP-0903 successfully reverses the mesenchymal phenotype and extends survival in preclinical models of advanced ovarian cancer
Nozomi Tomimatsu et al.
CANCER RESEARCH (2019)
Discovery of N-[4-(Quinolin-4-yloxy)phenyl]benzenesulfonamides as Novel AXL Kinase Inhibitors
Istvan Szabadkai et al.
JOURNAL OF MEDICINAL CHEMISTRY (2018)
Axl inhibitors as novel cancer therapeutic agents
Yingying Shen et al.
LIFE SCIENCES (2018)
Kinase-targeted cancer therapies: progress, challenges and future directions
Khushwant S. Bhullar et al.
MOLECULAR CANCER (2018)
Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors
Min Jung Choi et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2018)
Anexelekto /MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
Peter P. Ruvolo et al.
HAEMATOLOGICA (2017)
The Axl kinase domain in complex with a macrocyclic inhibitor offers first structural insights into an active TAM receptor kinase
Ketan S. Gajiwala et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2017)
AXL-GAS6 expression can predict for adverse prognosis in non-small cell lung cancer with brain metastases
Xiaoliang Wu et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2017)
Phosphatidylserine Is the Signal for TAM Receptors and Their Ligands
Greg Lemke
TRENDS IN BIOCHEMICAL SCIENCES (2017)
Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies
Marie Schoumacher et al.
CURRENT ONCOLOGY REPORTS (2017)
Macrophages promote the progression of premalignant mammary lesions to invasive cancer
Emily C. Carron et al.
ONCOTARGET (2017)
Anexelekto /MER tyrosine kinase inhibitor ONO-7475 arrests growth and kills FMS-like tyrosine kinase 3-internal tandem duplication mutant acute myeloid leukemia cells by diverse mechanisms
Peter P. Ruvolo et al.
HAEMATOLOGICA (2017)
Potent preclinical antitumor activity of MGCD265, an oral Met/VEGFR kinase inhibitor in phase II clinical development, in combination with taxanes or erlotinib.
J. M. Besterman et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).
H. A. Wakelee et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
AXL-Driven EMT State as a Targetable Conduit in Cancer
Jane Antony et al.
CANCER RESEARCH (2017)
Discovering novel 7-azaindole-based series as potent AXL kinase inhibitors
Clemence Feneyrolles et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
Structure-based optimization of 1H-imidazole-2-carboxamides as Axl kinase inhibitors utilizing a Mer mutant surrogate
Walter Keung et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2017)
AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective
Samuel H. Myers et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Preclinical combination of TP-0903, an AXL inhibitor and B-PAC-1, a procaspase-activating compound with ibrutinib in chronic lymphocytic leukemia
Viralkumar Patel et al.
LEUKEMIA & LYMPHOMA (2016)
Role of the Receptor Tyrosine Kinase Axl and its Targeting in Cancer Cells
Cristina Corno et al.
CURRENT MEDICINAL CHEMISTRY (2016)
4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors
Li Tan et al.
JOURNAL OF MEDICINAL CHEMISTRY (2016)
Axl Receptor Axis: A New Therapeutic Target in Lung Cancer
Pavel A. Levin et al.
JOURNAL OF THORACIC ONCOLOGY (2016)
The Receptor Tyrosine Kinase AXL in Cancer Progression
Erinn B. Rankin et al.
CANCERS (2016)
Gilteritinib (ASP2215), a Novel FLT3/AXL Inhibitor: Preclinical Evaluation in Combination with Azacitidine in Acute Myeloid Leukemia
Yoko Ueno et al.
BLOOD (2016)
Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors
Sutapa Sinha et al.
CLINICAL CANCER RESEARCH (2015)
Enzymes: principles and biotechnological applications
Peter K. Robinson
UNDERSTANDING BIOCHEMISTRY: ENZYMES AND MEMBRANES (2015)
The Axl receptor tyrosine kinase is a discriminator of macrophage function in the inflamed lung
T. Fujimori et al.
MUCOSAL IMMUNOLOGY (2015)
Axl inhibition: a potential road to a novel acute myeloid leukemia therapy?
Melanie Janning et al.
EXPERT REVIEW OF HEMATOLOGY (2015)
Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells
Mikaella Vouri et al.
ONCOTARGET (2015)
Role of Flippases, Scramblases and Transfer Proteins in Phosphatidylserine Subcellular Distribution
Hannah M. Hankins et al.
TRAFFIC (2015)
Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers
Aude I. Segaliny et al.
JOURNAL OF BONE ONCOLOGY (2015)
Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?
Zheng Zhao et al.
ACS CHEMICAL BIOLOGY (2014)
MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation
Jin Kyung Rho et al.
CANCER RESEARCH (2014)
AXL Inhibition Sensitizes Mesenchymal Cancer Cells to Antimitotic Drugs
Catherine Wilson et al.
CANCER RESEARCH (2014)
AXL Mediates Resistance to Cetuximab Therapy
Toni M. Brand et al.
CANCER RESEARCH (2014)
Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma
Hsin-Jung Lee et al.
CARCINOGENESIS (2014)
NPS-1034, a novel MET inhibitor, inhibits the activated MET receptor and its constitutively active mutants
Jae-Sik Shin et al.
INVESTIGATIONAL NEW DRUGS (2014)
Structural Elucidation of the DFG-Asp in and DFG-Asp out States of TAM Kinases and Insight into the Selectivity of Their Inhibitors
Abdellah Messoussi et al.
MOLECULES (2014)
The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells
Magdalena Paolino et al.
NATURE (2014)
The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinoma
M. A. Cichon et al.
ONCOGENE (2014)
Axl-altered microRNAs regulate tumorigenicity and gefitinib resistance in lung cancer
Y. Wang et al.
CELL DEATH & DISEASE (2014)
The TAM family: phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer
Douglas K. Graham et al.
NATURE REVIEWS CANCER (2014)
TIG1 Promotes the Development and Progression of Inflammatory Breast Cancer through Activation of Axl Kinase
Xiaoping Wang et al.
CANCER RESEARCH (2013)
Sequence Determinants of a Specific Inactive Protein Kinase Conformation
Sanjay B. Hari et al.
CHEMISTRY & BIOLOGY (2013)
An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers et al.
CLINICAL CANCER RESEARCH (2013)
Inhibition of Tumor Growth and Metastasis in Non-Small Cell Lung Cancer by LY2801653, an Inhibitor of Several Oncokinases, Including MET
Wenjuan Wu et al.
CLINICAL CANCER RESEARCH (2013)
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models
S. Betty Yan et al.
INVESTIGATIONAL NEW DRUGS (2013)
Axl Mediates Acquired Resistance of Head and Neck Cancer Cells to the Epidermal Growth Factor Receptor Inhibitor Erlotinib
Keith M. Giles et al.
MOLECULAR CANCER THERAPEUTICS (2013)
S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab
Mike F. Burbridge et al.
MOLECULAR CANCER THERAPEUTICS (2013)
First Axl inhibitor enters clinical trials
Cormac Sheridan
NATURE BIOTECHNOLOGY (2013)
The Receptor AXL Diversifies EGFR Signaling and Limits the Response to EGFR-Targeted Inhibitors in Triple-Negative Breast Cancer Cells
Aaron S. Meyer et al.
SCIENCE SIGNALING (2013)
IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations
Alejandro Vazquez-Martin et al.
SCIENTIFIC REPORTS (2013)
Impact of the small molecule Met inhibitor BMS-777607 on the metastatic process in a rodent tumor model with constitutive c-Met activation
Yao Dai et al.
CLINICAL & EXPERIMENTAL METASTASIS (2012)
Axl is essential for VEGF-A-dependent activation of PI3K/Akt
Guo-Xiang Ruan et al.
EMBO JOURNAL (2012)
A Novel Assay for the Met Inhibitory Activity of MGCD265 in Plasma From Solid Tumor Patients in a Dose Escalating Phase I Study
M. Fournel et al.
EUROPEAN JOURNAL OF CANCER (2012)
Hypoxia Stabilizes GAS6/Axl Signaling in Metastatic Prostate Cancer
Anjali Mishra et al.
MOLECULAR CANCER RESEARCH (2012)
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer
Zhenfeng Zhang et al.
NATURE GENETICS (2012)
VEGF and c-Met Blockade Amplify Angiogenesis Inhibition in Pancreatic Islet Cancer
Weon-Kyoo You et al.
CANCER RESEARCH (2011)
Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer
Razelle Kurzrock et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
G. Mudduluru et al.
ONCOGENE (2011)
Design, Synthesis, and Biological Evaluation of a Series of Novel AXL Kinase Inhibitors
Alexis Mollard et al.
ACS MEDICINAL CHEMISTRY LETTERS (2011)
Histological, molecular and functional subtypes of breast cancers
Gautam K. Malhotra et al.
CANCER BIOLOGY & THERAPY (2010)
R428, a Selective Small Molecule Inhibitor of Axl Kinase, Blocks Tumor Spread and Prolongs Survival in Models of Metastatic Breast Cancer
Sacha J. Holland et al.
CANCER RESEARCH (2010)
A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2
Joseph Paul Eder et al.
CLINICAL CANCER RESEARCH (2010)
BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth Factor-Stimulated Prostate Cancer Metastatic Phenotype In vitro
Yao Dai et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity
Amy K. Keating et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu et al.
CANCER RESEARCH (2009)
Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily
Gretchen M. Schroeder et al.
JOURNAL OF MEDICINAL CHEMISTRY (2009)
Antiangiogenic drugs and tyrosine kinases
Jozsef Timar et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2008)
Receptor tyrosine kinase inhibitors in thyroid cancer
Maria Domenica Castellone et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
The human receptor tyrosine kinase Axl gene-promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation
Giridhar Mudduluru et al.
BIOSCIENCE REPORTS (2008)
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Paolo M. Comoglio et al.
NATURE REVIEWS DRUG DISCOVERY (2008)
Immunobiology of the TAM receptors
Greg Lemke et al.
NATURE REVIEWS IMMUNOLOGY (2008)
Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer
Klarisa Rikova et al.
CELL (2007)
TAM receptors are pleiotropic inhibitors of the innate immune response
Carla V. Rothlin et al.
CELL (2007)
A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors
D. Mahadevan et al.
ONCOGENE (2007)
Identification of novel amplification gene targets in mouse and human breast cancer at a syntenic cluster mapping to mouse ch8A1 and human ch13q34
Martin C. Abba et al.
CANCER RESEARCH (2007)
Rational design of inhibitors that bind to inactive kinase conformations
Y Liu et al.
NATURE CHEMICAL BIOLOGY (2006)
Phosphoproteomic analysis of Her2/neu signaling and inhibition
Ron Bose et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival
P Vajkoczy et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Multiple roles for the receptor tyrosine kinase Axl in tumor formation
SJ Holland et al.
CANCER RESEARCH (2005)
Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor
PP Sainaghi et al.
JOURNAL OF CELLULAR PHYSIOLOGY (2005)
Ligand recognition and homophilic interactions in Tyro3 -: Structural insights into the Axl/Tyro3 receptor tyrosine kinase family
C Heiring et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts
J Stenhoff et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2004)
Met, metastasis, motility and more
C Birchmeier et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2003)
Serum-derived protein S binds to phosphatidylserine and stimulates the phagocytosis of apoptotic cells
HA Anderson et al.
NATURE IMMUNOLOGY (2003)
The protein kinase complement of the human genome
G Manning et al.
SCIENCE (2002)
Crystal structure of a C-terminal fragment of growth arrest-specific protein Gas6 -: Receptor tyrosine kinase activation by laminin G-like domains
T Sasaki et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast
G Berclaz et al.
ANNALS OF ONCOLOGY (2001)
Share Paper
